Asset Details
Do you wish to reserve the book?
Lung cancer organoids analyzed on microwell arrays predict drug responses of patients within a week
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Lung cancer organoids analyzed on microwell arrays predict drug responses of patients within a week
Do you wish to request the book?
Lung cancer organoids analyzed on microwell arrays predict drug responses of patients within a week
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Lung cancer organoids analyzed on microwell arrays predict drug responses of patients within a week
2021
Overview
While the potential of patient-derived organoids (PDOs) to predict patients’ responses to anti-cancer treatments has been well recognized, the lengthy time and the low efficiency in establishing PDOs hamper the implementation of PDO-based drug sensitivity tests in clinics. We first adapt a mechanical sample processing method to generate lung cancer organoids (LCOs) from surgically resected and biopsy tumor tissues. The LCOs recapitulate the histological and genetic features of the parental tumors and have the potential to expand indefinitely. By employing an integrated superhydrophobic microwell array chip (InSMAR-chip), we demonstrate hundreds of LCOs, a number that can be generated from most of the samples at passage 0, are sufficient to produce clinically meaningful drug responses within a week. The results prove our one-week drug tests are in good agreement with patient-derived xenografts, genetic mutations of tumors, and clinical outcomes. The LCO model coupled with the microwell device provides a technically feasible means for predicting patient-specific drug responses in clinical settings.
The lengthy time in establishing patient-derived organoids(PDOs) hampers the implementation of PDO-based drug sensitivity tests in clinics. Here, the authors show a microwell array-based method to predict patient’s responses to anti-cancer therapies in a week using lung cancer organoids.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ 49
/ Adenocarcinoma - drug therapy
/ Animals
/ Antineoplastic Agents - pharmacology
/ Arrays
/ Biopsy
/ Carcinoma, Squamous Cell - drug therapy
/ Carcinoma, Squamous Cell - genetics
/ Carcinoma, Squamous Cell - metabolism
/ Carcinoma, Squamous Cell - pathology
/ Cell Culture Techniques - methods
/ Cell Proliferation - drug effects
/ Drug Screening Assays, Antitumor - instrumentation
/ Drug Screening Assays, Antitumor - methods
/ Humanities and Social Sciences
/ Humans
/ Lung Neoplasms - drug therapy
/ Male
/ Mice
/ Mutation
/ Science
/ Tumors
